# US 2026/0098028 A1 · Compounds and Their Use for Treatment of Hemoglobinopathies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098028 A1
- Document ID: US20260098028A1
- Status: Published application
- Kind: A1
- Application number: 19/328,416
- Filed: 2025-09-15
- Published: 2026-04-09
- Earliest claimed: 2022-11-04
- Assignees: Bristol-Myers Squibb Company
- Applicants: Bristol-Myers Squibb Company
- Inventors: Thomas J. Cummins; Antonia Lopez-Girona; Scott Arne Johnson; Hannah L. Powers; Giorgio Tamo
- Web page: https://patentgrep.com/patent/US20260098028A1

## CPC

- C07D 401/14: containing three or more hetero rings
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- A61P 7/06: Antianaemics
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are compounds and methods for the prevention and/or treatment of hemoglobinopathies. Also provided herein are such compounds for use in such methods. Also disclosed herein are pharmaceutical compositions comprising such compounds for use in such methods of preventing or treating hemoglobinopathies.

## Claims

### Claim at position 1

-27. (canceled)

### Claim 28

A method of treating a hemoglobinopathy, comprising administering to a subject in need thereof a compound according to Formula (III):
or a pharmaceutically acceptable salt, thereof,
wherein:
Q″ is H or CH3;
R12 is
wherein
Q3 is selected from H, Cl, or F;
Q4 is selected from H, CH3, or CH(F)2;
Q5 is selected from H, CH3, or OCH3; and
Q6 is selected from H or F;
wherein the hemoglobinopathy is anemia, sickle cell disease, thalassemia, alpha-thalassemia, or beta-thalassemia.

### Claim 29 (depends on 28)

The method of claim 28, wherein Q″ is H.

### Claim at position 4

-34. (canceled)

### Claim 35 (depends on 28)

The method of claim 28, wherein Q3 is F.

### Claim 36 (depends on 28)

The method of claim 28, wherein Q5 is OCH3 or CH3.

### Claim at position 7

-46. (canceled)

### Claim 47

A method of treating a hemoglobinopathy, comprising administering to a subject in need thereof a compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof, wherein the hemoglobinopathy is anemia, sickle cell disease, thalassemia, alpha-thalassemia, or beta-thalassemia.

### Claim at position 9

48-68. (canceled)

### Claim 69

A method of inducing HbF expression in a cell, and/or decreasing ZBTB7A expression in a cell, and/or decreasing WIZ expression in a cell, comprising contacting a cell with a compound according to Formula (III):
or a pharmaceutically acceptable salt, tautomer, isotopologue, or stereoisomers thereof,
wherein:
Q″ is H or CH3;
R12 is a substituted or unsubstituted pyridyl, a substituted or unsubstituted alkyl, a substituted or unsubstituted heterocyclyl, or a substituted or unsubstituted C3-C6 cycloalkyl,
wherein
Q3 is selected from H, Cl, or F;
Q4 is selected from H, CH3, or CH(F)2;
Q5 is selected from H, CH3, or OCH3; and
Q6 is selected from H or F.

### Claim at position 11

-81. (canceled)

### Claim 82 (depends on 28)

The method of claim 28, further comprising administering to the subject in need thereof a second active agent and/or therapy.

### Claim 83 (depends on 82)

The method of claim 82, wherein the second active agent and/or therapy is luspatercept, voxelotor, crizanlizumab-tmca, hydroxyurea, L-glutamine, etavopivat, mitapivat, osivelotor, inclacumab, a blood transfusion, a stem cell transplant, a bone marrow transplant, or a gene therapy.

### Claim at position 14

-95. (canceled)

### Claim 96 (depends on 82)

The method of claim 82, wherein the second active agent and/or therapy is a gene therapy, and the gene therapy is a CRISPR therapy.

### Claim 97 (depends on 28)

The method of claim 28, wherein the hemoglobinopathy is anemia.

### Claim 98 (depends on 28)

The method of claim 28, wherein the hemoglobinopathy is sickle cell disease.

### Claim 99 (depends on 28)

The method of claim 28, wherein the hemoglobinopathy is thalassemia.

### Claim 100 (depends on 28)

The method of claim 28, wherein the hemoglobinopathy is alpha-thalassemia.

### Claim 101 (depends on 28)

The method of claim 28, wherein the hemoglobinopathy is beta-thalassemia.

### Claim 102 (depends on 47)

The method of claim 47, comprising administering to the subject a compound of the following structure:
or a pharmaceutically acceptable salt thereof, wherein the hemoglobinopathy is anemia, sickle cell disease, thalassemia, alpha-thalassemia, or beta-thalassemia.

### Claim 103 (depends on 102)

The method of claim 102, comprising administering to the subject a pharmaceutically acceptable salt of the compound of the following structure:

### Claim 104 (depends on 102)

The method of claim 102, comprising administering to the subject a compound of the following structure:

### Claim 105 (depends on 47)

The method of claim 47, comprising administering to the subject a compound of the following structure:
or a pharmaceutically acceptable salt thereof, wherein the hemoglobinopathy is anemia, sickle cell disease, thalassemia, alpha-thalassemia, or beta-thalassemia.

### Claim 106 (depends on 105)

The method of claim 105, comprising administering to the subject a pharmaceutically acceptable salt of the compound of the following structure:

### Claim 107 (depends on 105)

The method of claim 105, comprising administering to the subject a compound of the following structure:

### Claim 108 (depends on 102)

The method of claim 102, wherein the hemoglobinopathy is sickle cell disease.

### Claim 109 (depends on 103)

The method of claim 103, wherein the hemoglobinopathy is sickle cell disease.

### Claim 110 (depends on 104)

The method of claim 104, wherein the hemoglobinopathy is sickle cell disease.

### Claim 111 (depends on 105)

The method of claim 105, wherein the hemoglobinopathy is sickle cell disease.

### Claim 112 (depends on 106)

The method of claim 106, wherein the hemoglobinopathy is sickle cell disease.

### Claim 113 (depends on 107)

The method of claim 107, wherein the hemoglobinopathy is sickle cell disease.
